[The evaluation of the specific activity and side effects of the m-cholinergic blocker pentifin compared to other antiparkinson agents].
Experiments on rodents showed that pentifin, a muscarine antagonist belonging to the group of acetylene amines, possesses a pronounced antiparkinsonian activity. Pentifin is superior in the breadth of therapeutic action and tolerance characteristics to the conventional agents used for Parkinson's disease treatment.